American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. - Wikidata - wikimedia - TriplyDB

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

http://www.wikidata.org/entity/Q33382043

about

Interventions for preventing neuropathy caused by cisplatin and related compounds Interventions for preventing neuropathy caused by cisplatin and related compounds Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.Oral Mucositis Induced By Anticancer Therapies Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer Therapy Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer Cardiac toxicity in cancer survivors Cardiac effects of anticancer therapy in the elderly Mechanisms of Cisplatin nephrotoxicity Treatment of Radiation Injury Cardio-Oncology: A Focused Review of Anthracycline-, Human Epidermal Growth Factor Receptor 2 Inhibitor-, and Radiation-Induced Cardiotoxicity and Management Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs An integrated view of cisplatin-induced nephrotoxicity and ototoxicity Considering renal risk while managing cancer.Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention Management of chemotherapy induced cardiomyopathy.Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.Cardiomyocyte death in doxorubicin-induced cardiotoxicity Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study.Mitigation effect of an FGF-2 peptide on acute gastrointestinal syndrome after high-dose ionizing radiation.Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Dexrazoxane for the treatment of chemotherapy-related side effects.Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Potential interactions of prescription and over-the-counter medications having antioxidant capabilities with radiation and chemotherapy.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy.Are cancer stem cells radioresistant?Radioprotectors and mitigators of radiation-induced normal tissue injury Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005.Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Cardiovascular complications of breast cancer therapy in older adults A new posture-correcting system using a vector angle model for preventing forward head posture.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.

P2860

Q24197763-68DA2F0E-19B9-46E9-813A-89F82E229A67 Q24236661-1DD52CC7-5F79-4333-9371-392DAA67EE8E Q24615296-58641C8A-F185-4CBB-9867-AC769AB602A9 Q26742059-49B9A95E-B23C-41D9-AE92-225D133EA099 Q26777493-3FBEB168-0BA1-4779-A453-220D236ED4EA Q26797138-1580DD1E-FAD2-4D86-B46B-0B52ABE1FEE5 Q26821956-9D83FF43-46AE-4781-8417-6C4E099809E5 Q26851957-73E17822-4528-497C-8CF8-4C45E263BF72 Q26863244-684DFF45-7AAB-4620-8015-61F0BF2873EB Q26996320-55F9EB8B-233B-418F-BF22-9AF74268081F Q27003920-625B0AE1-80F5-4843-9F47-D66CEE5DF560 Q28068290-61807C59-BA5E-4251-AA6A-657438CABC34 Q28070311-C284E72C-7C07-4E67-A985-A94C4AFA0D5F Q28080615-9FC14B66-9EB7-44EC-8A8B-E9F231AFEBE6 Q30234338-1CAEAF35-8AA6-43A6-8BE5-C88F8DDBD402 Q30399577-31A25C7D-8FFB-4FBF-8984-F85BCA9B2623 Q30461441-8A001FFE-C090-464B-96CB-5BD6E108D706 Q33399402-39B46D0A-E40B-4854-8D21-094463F88D33 Q33604134-D1BFAA20-AE6B-4F02-A69B-399E3A451EA0 Q33752979-1404C057-8AE8-448E-A1CE-8C0E4C161965 Q33903790-A5A64D8F-E807-4EC8-B707-6BD3D1306D90 Q34073681-39F2B290-9282-4639-9391-E7A90D0D294D Q34211957-1D71B263-D4EA-4976-96C2-F1DE76B0CCD8 Q34242059-F6A01342-185D-4F70-B8FF-796BB52BCCD1 Q34362184-11058734-39A4-4169-A6F7-0DBEEA9504BB Q34438605-48B2104C-393B-4F01-A4A3-94E69DD5240B Q34466688-AC0258DB-2524-4413-8115-85F0FD240188 Q34625462-D6CC91EF-6414-4FFE-B6A6-80B52ABFD1E1 Q34686233-54F082F8-62E5-4C34-AFC8-DD8AF2F4A34F Q34790801-1A4BB4E3-AADD-4815-92AB-BDA1357754B6 Q35025569-4260FC9B-E941-48AA-BECF-98E8DADB25DE Q35076156-0039080C-B9EE-4C37-B299-38AF32687F7E Q35562745-686C8F00-FB92-4A50-A179-F52E94B1AC77 Q35584686-B9F7F0D1-CFF9-4A41-AE2B-0B9108B23154 Q35613536-3ED0F6DE-6385-4ABD-94C4-5002FF8CE964 Q35673260-8C004B94-FD2C-46FD-A484-6C0039D9A44B Q35842970-B0B4F8A6-8CA8-44E2-A30A-CB2C5A0F889A Q35849444-545A9920-8069-4098-BF83-F5A600872A6B Q35947024-0D700CF3-4C9F-4D45-B41F-9D5004C964D1 Q36099606-194CA10C-B203-416E-8E5C-C23BDF95A019

P2860

American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.

http://www.wikidata.org/entity/Q33382043

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

American Society of Clinical O ...... radiation therapy protectants.

@ast

American Society of Clinical O ...... radiation therapy protectants.

@en

type

label

American Society of Clinical O ...... radiation therapy protectants.

@ast

American Society of Clinical O ...... radiation therapy protectants.

@en

prefLabel

American Society of Clinical O ...... radiation therapy protectants.

@ast

American Society of Clinical O ...... radiation therapy protectants.

@en

P1433

Q33382043-99CD53CD-02E6-41DC-A063-793880D32EDE

P1476

Q33382043-25593AAE-7C2F-44DC-BA93-DF13BC0B5E34

P2093

Q33382043-026DD1F1-4058-4B6B-8923-55F85CEEEF39

Q33382043-374047E6-A9AD-48E9-8FC2-6C981B9532BD

Q33382043-57EB5EF5-9AFA-4774-9302-C605D3F991C0

Q33382043-6D860D1C-90CF-41E8-8219-D0027A21E852

Q33382043-6EBBF333-D09A-4B95-8528-DB1A1660E41F

Q33382043-714A4FA3-3AA0-4025-BC88-B1508B048D8F

Q33382043-8770F23B-BE0A-4BCB-A027-E01ACBC9DB80

Q33382043-945770D0-A3EA-4CF8-862C-68DD2019C8BA

Q33382043-972D63BA-E375-48CC-9DDD-8BF48FCDC149

Q33382043-EA3557C7-F422-4687-86BE-E9CD961871D7

P304

Q33382043-334CDB44-ACD5-460F-949E-57E5A56411A6

P31

Q33382043-C75A454B-A93F-4AD5-9FD2-9A84D3E96589

P356

Q33382043-8E80FCC0-933C-4B15-ADD0-CB7258B0A39C

P407

Q33382043-6BE0EF9E-26C4-4A63-BCF2-F3FEFFBE1191

P433

Q33382043-D9907519-9488-4496-9F6C-537B24E24AFF

P478

Q33382043-A43F6860-F88D-4E06-822B-39A8B9E7702F

P577

Q33382043-18A83338-BBA0-4125-A8D3-15DC602A2889

P698

Q33382043-B46E76E0-296D-460C-BF17-9EDFFDD644FA

P921

Q33382043-06C2D759-3460-4CB5-9B57-28B8919D75C7

Q33382043-5A12FA07-EC83-4F0E-B4F2-2FAF53F5A4B2

P356

JCO.2008.17.2627

P1433

Journal of Clinical Oncology

P1476

American Society of Clinical O ...... radiation therapy protectants.

@en

P2093

Andy Trotti

http://www.w3.org/2001/XMLSchema#string

Bahman Emami

http://www.w3.org/2001/XMLSchema#string

Daniel M Green

http://www.w3.org/2001/XMLSchema#string

Daniel von Hoff

http://www.w3.org/2001/XMLSchema#string

Gary I Cohen

http://www.w3.org/2001/XMLSchema#string

J Tate Thigpen

http://www.w3.org/2001/XMLSchema#string

Karen L Hagerty

http://www.w3.org/2001/XMLSchema#string

Lynn M Schuchter

http://www.w3.org/2001/XMLSchema#string

Martee L Hensley

http://www.w3.org/2001/XMLSchema#string

Neal J Meropol

http://www.w3.org/2001/XMLSchema#string

P304

127-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.17.2627

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19018081

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy